Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: The ESPIA questionnaire

Justicia, José L; Cardona, Victòria; Guardia, P.; Ojeda, Pedro; Olaguibel, José María; Vega, José M.; Vidal, Carmen; Baró, Eva; Garcia, Mario

doi:10.1016/j.jaci.2012.11.049

Cited by 20 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, the only established therapy option for the treatment of allergies is conventional allergen immunotherapy (AIT) with allergen extracts. However, AIT is not convenient for patients due to a multi-year treatment regimen, for some allergies only partially efficacious, and can be hampered by severe allergic side effects 13 , 14 . To improve AIT, novel vaccine candidates and accompanying adjuvants that increase efficacy while decreasing unwanted adverse-effects are needed 15 .…”

Section: Introductionmentioning

confidence: 99%

Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo

Schülke

Kuttich

Wolfheimer

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Allergies to weed pollen including members of the Compositae family, such as mugwort, ragweed, and feverfew are spreading worldwide. To efficiently treat these newly arising allergies, allergen specific immunotherapy needs to be improved. Therefore, we generated novel vaccine candidates consisting of the TLR5-ligand Flagellin A from Listeria and the major mugwort allergen Art v 1 including either the wild type Art v 1 sequence (rFlaA:Artv1) or a hypoallergenic variant (rFlaA:Artv1hyp) with reduced IgE-binding capacity. Immune modulating capacity of these constructs and respective controls was evaluated in vitro and in vivo. Incorporation of hypoallergenic Art v 1 derivative did not interfere with the resulting fusion proteins’ immune stimulatory capacity. Both rFlaA:Artv1 and rFlaA:Artv1hyp induced a prominent, mTOR-dependent, IL-10 secretion from murine dendritic cells, and suppressed allergen-specific TH2-cytokine secretion in vitro and in vivo. Both conjugates retained the capacity to induce rFlaA-specific antibody responses while efficiently inducing production of Art v 1-specific IgG1 and IgG2a antibodies in mice. Interestingly, only the suppression of TH2-cytokine secretion by rFlaA:Artv1 (but not rFlaA:Artv1hyp) was paralleled by a strong secretion of IFN-γ. In summary, we provided evidence that incorporating hypoallergens into flagellin:allergen fusion proteins is a suitable strategy to further improve these promising vaccine candidates.

show abstract

Section: Introductionmentioning

confidence: 99%

Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo

Schülke

Kuttich

Wolfheimer

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Allergen immunotherapy (AIT) with allergen extracts can lead to unwanted side‐effects and can be a multiyear ordeal for patients . Increasingly, however, AIT has been moving toward the use of optimized products to increase the efficacy, while decreasing unwanted adverse effects .…”

mentioning

confidence: 99%

MPLA shows attenuated pro‐inflammatory properties and diminished capacity to activate mast cells in comparison with LPS

Schülke

Flaczyk

Vogel

et al. 2015

Allergy

View full text Add to dashboard Cite

show abstract

“…В настоящее время для оценки удовлетворенности проведенным лечением у пациентов с аллергическим ринитом разработан опросник, содержащий 16 пун-ктов -Шкала удовлетворенности для пациента, полу-чающего АСИТ (Satisfaction Scale for Patients Receiving Allergen Immunotherapy, ESPIA) [36]. Также разработан Индекс преимуществ пациента (Patient Benefit Index, PBI) [37], который состоит из 25 вопросов, на которые необходимо ответить дважды -до и после терапии.…”

Section: удовлетворенность пациентов лечениемunclassified

“…Также разработан Индекс преимуществ пациента (Patient Benefit Index, PBI) [37], который состоит из 25 вопросов, на которые необходимо ответить дважды -до и после терапии. Опросники ретроспективно дают возможность оценить ответ на терапию у конкретного пациента; анкеты просты и быстры в использовании, валидированы, коррелируют с клиническим улучшением и с показателями качества жизни [36][37][38].…”

Section: удовлетворенность пациентов лечениемunclassified

Allergen-Specific Immunotherapy in Children. Standardizing the Efficacy Evaluation Approaches

Вишнева¹,

Намазова-баранова²,

Алексеева³

et al. 2015

PPh

View full text Add to dashboard Cite

Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: The ESPIA questionnaire

Cited by 20 publications

References 21 publications

Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo

Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo

MPLA shows attenuated pro‐inflammatory properties and diminished capacity to activate mast cells in comparison with LPS

Allergen-Specific Immunotherapy in Children. Standardizing the Efficacy Evaluation Approaches

Contact Info

Product

Resources

About